Showing 4531-4540 of 7288 results for "".
- FDA Accepts sNDA for Roflumilast Cream for AD Patients Ages 2-5https://practicaldermatology.com/news/FDA-Accepts-sNDA-Roflumilast-Cream-AD-Patients-Ages-2-5/2471351/The US Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) for ZORYVE (roflumilast) cream 0.05%, for the topical treatment of mild to moderate atopic dermatitis (AD) in children 2 to 5 years old, Arcutis Biotherapeutics, Inc. announced. The FDA has se
- New INTEGUMENT-PED Results Support Roflumilast Cream for Pediatric ADhttps://practicaldermatology.com/news/phase-3-trial-supports-roflumilast-cream-for-young-children-with-ad/2471293/Arcutis Biotherapeutics announced today that the INTEGUMENT-PED Phase 3 trial had met its primary endpoint, according to a release from the manufacturer. Researchers on the study evaluated the efficacy and safety of roflumilast cr
- Analysis: Sustained Eczema and Psoriasis Remission Achieved with Dupilumabhttps://practicaldermatology.com/news/analysis-sustained-eczema-and-psoriasis-remission-achieved-with-dupilumab/2471286/A new study highlights the potential of dupilumab to deliver sustained remission in children with moderate-to-severe atopic dermatitis (AD). The findings, presented as a poster at the 2025 Masterclasses in Dermatology conference
- EFFISAYIL 2 Data Suggest Unmet Needs in Generalized Pustular Psoriasis Carehttps://practicaldermatology.com/news/effisayil-2-data-suggest-unmet-needs-in-generalized-pustular-psoriasis-care/2471250/Baseline data from the EFFISAYIL 2 trial suggested that traditional small-molecule therapies fail to adequately address the burden of generalized pustular psoriasis (GPP). The analysis, presented as a poster at Masterclas
- Dr. Lebwohl: Don't Delay GPP Treatment for TB Testing or Skin Biopsyhttps://practicaldermatology.com/news/Dr-Lebwohl-Dont-Delay-GPP-Treatment-TB-Testing-Skin-Biopsy/2471222/Generalized pustular psoriasis (GPP) treatment should not be delayed while waiting for a tuberculosis screening, according to Mark Lebwohl, MD. Speaking at the Winter Clinical Hawaii 2025 meeting in Waikoloa Village, Hawaii, Dr. Lebwohl recommended initiating spesolimab therapy immediately
- Care Urged for Adult-Onset AD Diagnoseshttps://practicaldermatology.com/news/Care-Urged-Adult-Onset-AD-Diagnoses/2471216/As revolutionary as the latest approved therapeutics for atopic dermatitis have been, Daniela Kroshinsky, MD, MPH, cautioned that dermatologists must be vigilant and consider biopsies for atypical or nonresponsive cases before starting dupilumab or a JAK inhibitor. Speaking at the Winter C
- Weight-Loss Drugs Highlighted as 'Easy' Option to Improve PsO Therapieshttps://practicaldermatology.com/news/Weight-Loss-Drugs-Highlighted-Easy-Option-Improve-PsO-Therapies/2471215/Any dermatologist not prescribing weight-loss drugs for psoriasis patients who are obese likely will be soon, according to Mark Lebwohl, MD. Dr. Lebwohl, speaking at the Winter Clinical Hawaii 2025 meeting in Waikoloa Village, Hawaii, highlighted data indicating an association between como
- Dr. Armstrong Discusses Combination Therapies for Psoriasishttps://practicaldermatology.com/news/Dr-Armstrong-Discusses-Combination-Therapies-Psoriasis/2471212/The quality and variety of biologic therapeutic options available today should give dermatologists more confidence than ever in treating psoriasis, according to April Armstrong, MPH, MPH. Speaking at the Winter Clinical Hawaii 2025 meeting in Waikoloa Village, Hawaii, Dr. Armstrong discuss
- Dr. Swanson: Dupilumab/Vaccines Question Has Been Answeredhttps://practicaldermatology.com/news/Dr-Swanson-Dupilumab-Vaccines-Question-Has-Been-Answered/2471166/The biggest remaining question about dupilumab has been answered by the allergy and immunology community, Practical Dermatology Associate Medical Editor Elizabeth (Lisa) Swanson, MD, FAAD, said at the Winter Clinical Hawaii 2025 meeting in Waikoloa Village, Hawaii. “The only realy question
- POETYK-PSO LTE: No New Safety Signals for Deucravacitinib at Five Yearshttps://practicaldermatology.com/news/poetyk-lte-no-new-safety-signals-for-deucravacitinib-at-five-years/2471170/Sotyktu (deucravacitinib) showed sustained efficacy and an acceptable safety profile over a period of 5 years in adults with moderate-to-severe plaque psoriasis, according to an announcement by Bristol Myers Squibb. Based on rec